The first generation of epigenetic modulators approved for clinical treatment includes nonselective DNMT and HDAC inhibitors for myelodysplastic syndrome and cutaneous T cell lymphoma [142, 143]. Here, DNMT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.